Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EASE SBS 3 Long-term Extension Trial of Glepaglutide in Short Bowel Syndrome
2024-513373-43-00Phase 3Completed
- Sponsor
- Zealand Pharma
- Start
- Sep 2024
- Modality
- Peptides
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of glepaglutide in short bowel syndrome (SBS), sponsored by Zealand Pharma. Primary endpoint: Incidence and type of adverse events. Started Sep 2024; status: completed.
02
Drugs
glepaglutide
03
Conditions
short bowel syndrome (SBS)
Beyond the preview
Go deeper on 2024-513373-43-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513373-43-00.